Skip to content

Feasibility and Usability of Mobile Applications for Monitoring Cutaneous Leishmaniasis Treatment in Colombia

Feasibility and Usability of Mobile Applications for Monitoring Cutaneous Leishmaniasis Treatment in Colombia: 2019-2021

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05533736
Enrollment
105
Registered
2022-09-09
Start date
2020-03-01
Completion date
2021-12-01
Last updated
2022-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneous Leishmaniasis, American

Brief summary

An effectiveness-implementation sequential explanatory hybrid design type 2 was performed in two rural communities of Colombia. A quasi-experimental study with historical control (standard of care) was designed to estimate the effectiveness of community-based intervention using the Guaral+ST mobile application (app). Three implementation outcomes were evaluated: acceptability and usability by qualitative methods, and fidelity by quantitative methods

Detailed description

An effectiveness-implementation sequential explanatory hybrid design type 2 using mixed methods was performed in 2020 and 2021 in two study sites: Pueblo Rico, Risaralda, and Rovira, Tolima. A quasi-experimental study with historical control (standard of care) was designed to evaluate the effectiveness of the community-based intervention supported by mHealth, in terms of monitoring of treatment of patients with cutaneous leishmaniasis. The effectiveness indicators i. number of follow-up contacts, ii. Adherence to treatment, iii. adverse drug reactions, and iv. the therapeutic response were compared between the intervention and control groups. After the effectiveness evaluation was completed, three outcomes were assessed to inform the implementation of the community-based use of the app: acceptability, usability, and fidelity.

Interventions

OTHERCommunity based strategy to follow-up pactientes with Cutaneous Leishmaniasis

Community Health leaders follow patients using the Guaral+ST app at final of treatment, and on days 90 and 180 after initiating the treatment.

Sponsors

Universidad Icesi
CollaboratorOTHER
Centro Internacional de Entrenamiento e Investigaciones Médicas
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

Patients followed by CHL with the app (effectiveness evaluation): * Diagnosis confirmed by microscopy of tissue smear or culture * Any age and gender * Medical prescription for antileishmanial treatment * Approved and signed informed consent * Availability of CHL to monitor treatment of the patients in the community Inclusion Criteria patients who received the standard of care (effectiveness evaluation): * Clinical records of patients with confirmed CL at most two years prior to the start of this study * Any age and gender * Received antileishmanial treatment based on national guidelines Inclusion criteria for participants of implementation evaluation (Community Health Leaders) * Residents of the rural areas of study sites * Voluntary participation in the monitoring of patients using the mobile app

Design outcomes

Primary

MeasureTime frameDescription
The effectiveness of community-based intervention using the Guaral+ST mobile application was evaluated by four outcomes: i. The number of follow-ups6 monthsThe number of follow-up contacts between patients and health system or community health workers.
ii. Percent adherence to treatment6 monthsRelation between the number of doses administrated and the number of doses formulated by the physicians x 100.
iii. Adverse drug reactions6 monthsFrequency of adverse drug reactions: number of adverse drug reactions
iv. Therapeutic response6 months* Cure: Completely re-epithelialised lesions on days 90 -180 after initiation of treatment * Failure: \>50% increase in ulcer size from baseline at any time during evaluation or incomplete re-epithelialised on days 90-180

Secondary

MeasureTime frameDescription
ii. Usability6 monthsRefers to the degree to which the app can be used by community health leaders and health workers to achieve quantified objectives of effectiveness, efficiency, and satisfaction. It was evaluated using qualitatively at two levels: community health leaders and health workers.
iii. Fidelity6 monthsIt refers to the compliance (percentage) with the implementation strategy as described in the protocol. It was measured at two levels: Community Health Leaders and physicians.
Implementation of the community-based strategy to follow patients with cutaneous Leishmaniasis was evaluated by three outcomes. i. Acceptability6 monthsIt refers to the perception among implementation stakeholders that the app is appealing, suitable, or satisfactory by a qualitative evaluation at three levels: community health leaders, health workers, and, and patients.

Countries

Colombia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026